Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:08:17.808Z.
Calculation as of: 2026-10-06T16:08:17.808Z.
Quote observation: 2026-10-06T16:05:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6608cd76dc650ef8b2fc8232603ca313d9f3e0951a45c9e65e7ec74b346396eb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$15.30M
EV/FCF Ratio
N/A
TTM Avg
97.85x
3Y Avg
97.85x
5Y Avg
97.85x
Market Cap
$14.44M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.97M
EV/FCF Ratio
11.62x
TTM Avg
13.15x
3Y Avg
13.15x
5Y Avg
13.15x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $15.18M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | N/A | 97.85x | 97.85x | 97.85x |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.52M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | N/A | N/A | N/A | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.05M | N/A | 79.94x | 79.62x | 79.62x |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 11.62x | 13.15x | 13.15x | 13.15x |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.88M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
